The global immunohistochemistry (IHC) market is poised for significant growth, with an expected value of USD 3.5 billion in 2024. With a projected moderate compound annual growth rate (CAGR) of 7.8%, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Needham analyst Michael Matson reiterated a Buy rating on NeoGenomics (NEO – Research Report) today and set a price target of $19.00.Stay Ahead ...

The following is a summary of “Biological characterization and clinical significance of cuproptosis-related genes in lung ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on NeoGenomics (NEO – Research Report). The company’s shares ...

Advancements in targeted therapies have transformed the treatment landscape for NSCLC, enabling precision medicine approaches that improve outcomes. These therapies focus on specific genetic mutations ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange ...

USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted ...